Closing the AYA Gap: Clinical Trials, Genetic Testing, and Palliative Care for Young Sarcoma Patients
A new educational review in the American Society of Clinical Oncology Educational Book, authored by Sophie Jessop, MBBS, and colleagues, examines three persistent gaps in care for adolescents and young adults (AYAs) with sarcoma: clinical trial access, genetic testing for inherited cancer risk, and timely palliative care. The piece is grounded by the firsthand perspective of Courtney Fullbright, a patient advocate and Ewing sarcoma survivor.
The Clinical Trial Gap
AYAs (ages 15-39) have long missed the survival gains seen in younger and older patients. Sarcoma is a key test case, representing 5-11% of AYA cancers despite its overall rarity. The 2014 National Clinical Trials Network (NCTN) aimed to fix this through broadened eligibility and cross-group collaboration, but early efforts revealed friction, including eligibility confusion and low community-site participation. Despite reforms, AYA enrollment in sarcoma trials has not meaningfully improved and has declined in some categories.
Genetic Testing Deserves a Routine Place
Sarcoma is a “high-yield” context for germline testing: 10-20%, and in some cohorts over half, of patients carry a pathogenic germline variant, often without any family history to suggest it. Beyond TP53 and Li-Fraumeni syndrome, the review covers NF1, hereditary retinoblastoma, DICER1 syndrome, and newer genes like SMARCAL1. Current guidelines remain syndrome-driven rather than tumor-driven, a gap the authors say should close, especially for AYAs who often fall between pediatric and adult testing frameworks.
Palliative Care Needs to Start Earlier
AYAs with sarcoma face significant symptom burden and psychosocial distress, yet palliative care often arrives late: over half weren’t referred until their second year of treatment in one study, despite most adolescents wanting these conversations early. Patients who received palliative care lived roughly 200 days longer in one study. Tools like Voicing My Choices, FACE, and PRISM-AC offer evidence-based ways to start these conversations sooner.
Why This Matters for the SS Community
Synovial sarcoma most commonly affects people ages 20-39, squarely within the AYA population this review addresses. Better trial access, routine germline testing regardless of family history, and earlier palliative care all apply directly to younger synovial sarcoma patients navigating the same gaps between pediatric and adult systems.
For more information, read the full article in the ASCO Educational Book. For more information about the Synovial Sarcoma Foundation, please visit our website.
